Cancer Education
focusing on Specialized Topics of Interest

Taught by the Experts




www.BMLI.com

Symposium Co-Chairs

Leo I. Gordon, MD
Leo I. Gordon, MD
(Co-Chair)
Abby and John Friend Professor of Cancer Research
Professor in Medicine
Director Lymphoma Program
Co-Director Hematologic Malignancies Program
Division of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Medical Director of the John and Lillian Matthews Center for Cellular Therapy
Chicago, IL
Roy S Herbst MD PhD
Roy S. Herbst, MD, PhD
(Co-Chair)
Ensign Professor of Medicine
Professor of Pharmacology
Chief of Medical Oncology
Director, Thoracic Oncology Research Program
Associate Director for Translational Research
Translational Research Program, Yale Comprehensive Cancer Center
Yale School of Medicine
New Haven, CT

Medical Oncology Faculty

Ranjana H. Advani, MD
Ranjana H. Advani, MD
Saul Rosenberg Professor of Lymphoma
Physician Leader of the Lymphoma Clinical Care Program
National Comprehensive Cancer Network (NCCN) non Hodgkin and Hodgkin Lymphoma (vice chair) guidelines panel
Lymphoma Core Committee of the Eastern Cooperative Oncology Group (ECOG)
Co-Chair of the National Cancer Institute Lymphoma Steering Committee
Stanford School of Medicine
Stanford, CA
Philippe Armand, MD, PhD
Philippe Armand, MD, PhD
Assistant Professor
Department of Medicine
Harvard Medical School
Staff, Medical Oncology
Dana-Farber Cancer Institute
Boston, MA
Edward Garon, MD
Edward Garon, MD
Professor of Medicine and
Director, Department of Thoracic Oncology
UCLA Jonsson Cancer center
Los Angeles, CA
Corey J. Langer, MD
Corey J. Langer, MD
Professor of Medicine
University of Pennsylvania Hospital
Director, Thoracic Oncology
Abramson Cancer Center
Perelman Center for Advanced Medicine
Philadelphia, PA
Eileen M. O'Reilly, MD
Eileen M. O'Reilly, MD
Associate Director,
David M. Rubenstein Center for
Pancreatic Cancer Research
Memorial Sloan Kettering Cancer Center
New York, NY
John M. Pagel, MD, PhD Dsc
John M. Pagel, MD, PhD Dsc
Clinical Hematologist
Staff Physician
Swedish Cancer Institute
Seattle, WA
Daniel P. Petrylak, MD
Daniel P. Petrylak, MD
Professor of Medicine, Medical Oncology and Urology
Professor & Co-Director
Signal Transduction Research Program
Yale Comprehensive Cancer Center
Yale School of Medicine
New Haven, CT
Stanley R. Riddell, MD
Stanley R. Riddell, MD
Professor, School of Medicine
University of Washington
Seattle Cancer Care Alliance
Seattle, WA
Gregory J. Riely, MD, PhD
Gregory J. Riely, MD, PhD
Medical Oncologist
Thoracic Oncology Service
Vice Chair,
Clinical Trials Office
Department of Medicine
Memorial Sloan-Kettering Cancer Center
New York, NY
Mario Sznol, MD
Mario Sznol, MD
Professor of Medicine
Yale University School of Medicine
Co-Director, Yale SPORE in Skin Cancer
Yale Comprehensive Cancer Center
New Haven, CT
Margaret A. Tempero, MD
Margaret A. Tempero, MD
Director, UCFS Pancreas Center
Leader, Pancreas Cancer Program
Professor of Medicine
Division of Hematology and Oncology
University of California San Francisco
San Francisco, CA
Heather A. Wakelee, MD
Heather A. Wakelee, MD
Assistant Professor
Department of Medicine
Division of Oncology
Member, Stanford Cancer Institute
Stanford Clinical Cancer Center
Stanford, CA
Jeffrey S. Weber, MD., PhD
Jeffrey S. Weber, MD, PhD
Deputy Director, Laura & Isaac Perlmutter Cancer Center
Co-Director, Melanoma Program
Head of Experimental Therapeutics
NYU Langone NCI Comprehensive Cancer Center
New York, NY
H. Jack West, MD
H. Jack West, MD
Medical Director, Thoracic Oncology Program
Swedish Cancer Institute
President and CEO
Global Resource for Advancing Cancer Education
Seattle, WA
Jeffrey Wolf, MD
Jeffrey Wolf, MD
Clinical Professor, Department of Medicine,
Director, Myeloma Program
Helen Diller Family Comprehensive Cancer Center
University of California San Francisco
San Francisco, CA

Oncology Nursing Faculty

Marianne J. Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP
Marianne Davies, DNP, ACNP, AOCNP
Oncology Nurse Practitioner-Thoracic
Smilow Cancer Center at Yale New Haven
Yale Comprehensive Cancer Center
Assistant Professor
Yale School of Nursing
West Haven, CT

Oncology Pharmacist Faculty

Jim M. Koeller, MS
Jim M. Koeller, MS
Professor
University of Texas at Austin
College of Pharmacy
Pharmacotherapy Division
Adjoint Professor
University of Texas Health Science Center at San Antonio
School of Medicine
Pharmacotherapy Education & Research Center
University of Texas
Health Science Center at San Antonio
San Antonio, TX
  1. Only limited seating is available
  2. All discounts have been expired except group discounts
  3. Contact us for remaining group discounts
7:00AM Registration and Buffet Breakfast
8:00AM Welcome, Introductions and CME/CE Pre Test
Dr. Gordon
SESSION #1 LUNG CANCER: Immune Therapy and Novel Targeted and Novel Chemotherapy
(beginning with several “Rapid-Fire” Questions asked of the audience)
Chair: Dr. Wakelee
8:20AM DEBATE 1: Checkpoint antibodies are interchangeable regardless of PD-L1 status?
  • Yes - Dr. West
  • No - Dr. Riely
8:40AM Expert Panel Discussion and Q&A with Queued-Up Audience Questions
Dr. Wakelee
8:50AM Managing squamous and adenocarcinoma NSCLC patients who fail or relapse on checkpoint inhibition: What are the options with immune therapy, targeted therapy and chemotherapy?
Dr. Garon
9:10AM Strategies for managing NSCLC patients with acquired resistance (AR) to EGFR and ALK targeted therapy: What are the new standards of care? How does a clinician decide among five new EGFR agents for managing AR? What are the roles of immune therapy? liquid biopsies? NGS testing?
Dr. Riely
9:30AM The ever expanding number of actionable NSCLC mutations? How do we best address this issue with NGS testing and other emerging issues?
Dr. Wakelee
9:50AM Combination Strategies: What are the optimal strategies to combine immune therapies plus targeted therapies, and immune therapies with other immune therapies or chemotherapies?
Dr. Herbst
10:10AM Expert Panel Discussion and Q&A with Queued-Up Audience Questions
Dr. Herbst
10:25AM BREAK
SESSION #2 MELANOMA: Combinations of immune Therapy and Novel Targeted Therapy
(beginning with several “Rapid-Fire” Questions asked of the audience)
Chair: Dr. Weber
10:35AM DEBATE 2: Should targeted therapy or Immune-oncology therapy be used for treatment-naive BRAF-mutated metastatic melanoma?
  • Targeted - Dr. Sznol
  • Immuno therapy - Dr. Weber
10:50AM BRAF Wild type melanoma: What should be the first-line therapy for these patients: single-agent anti-PD-1 versus single-agent anti-CTLA4, oncoloytic viral therapy, versus their combination?
Dr. Weber
11:10AM Combinations and Sequencing of Immune therapy and/or targeted therapy: Matching patients and therapy
Dr. Sznol
11:30AM Expert Panel Discussion and Q&A with Queued-Up Audience Questions
Dr. Weber
11:45AM LUNCH WITH THE PROFESSORS -- 3 options: (all include CME/CE credit)
  • Buffet Lunch
  • All faculty & disciplines as desired
  • Pharmacy "Can a Clinical Value be Established for Immunotherapies?" (Jim Koeller)
  • Nursing: "The Role of the Nurse and Nurse Practitioner with Targeted and Immunotherapy for Cancer" (Marianne Davies)

Koeller & Davies
SESSION #3 HEMATOLOGIC MALIGNANCIES: New paradigms using immune & targeted therapies or combinations of both
(beginning with several “Rapid-Fire” Questions asked of the audience)
Chair: L. Gordon
12:45PM Scientific Rationale for Immunotherapy in Lymphoma: What are the current and emerging clinical applications?
Dr. Gordon & Dr. Advani
1:00PM DEBATE 3: Novel Immunotherapeutic Approaches vs Allogeneic Transplant in DLBCL and HL
  • Novel Immunotherapeutic Approaches - Dr. Armand
  • Allogeneic Stem Cell Transplantation - Dr. Gordon & Dr. Advani
1:15PM Checkpoint Blockade in Lymphoma
Dr. Armand
1:35PM The emerging clinical applications of immune therapy for leukemia: From CAR-T cells and other potential game-changing strategies
Dr. Riddell
1:50PM Clinical Applications of Targeted Therapies and Immune Therapies for Leukemia: Is a New paradigm Emerging?
Dr. Pagel
2:05PM Multiple Myeloma: Expanding the Therapeutic Options by Targeting SLAMF7, CD38, Checkpoint Inhibition and Other Targets with Immune or Targeted Therapy various combinations
Dr. Wolf
2:25PM Expert Panel Discussion and Q&A with Queued-Up Audience Questions
Dr. Gordon
2:40PM BREAK
SESSION #4 EMERGING STRATEGIES FOR SOLID MALIGNANCIES RESPODING TO IMMUNE & TARGETED ONCOLOGY THERAPY: PANCREATIC CANCER, BLADDER & RENAL CELL CANCERS, and HEAD & NECK CANCER
(beginning with several “Rapid-Fire” Questions asked of the audience)
Chair: E. O'Reilly
3:00PM G/U Malignancies: Bladder Cancer, Renal Cell Cancer, Prostate Cancer: Monotherapy, Combination Immune therapy and/or Targeted therapy-Checkpoint inhibition, Immunomodulatory & Vaccine strategies
Dr. Petrylak
3:20PM Q&A with Queued-Up Audience Questions
Dr. Petrylak
3:30PM DEBATE 4: Targeted therapy versus Immune Therapy for pancreatic cancer
  • Janus Kinase and Bruton's Tyrosine Kinase Inhibition - Dr. Tempero
  • Immune Therapy - O'Reilly
3:50PM Pancreatic Cancer: Applying the advances with translational biology strategies using novel immune and targeted therapies: How do we optimally integrate all of these new strategies?
Dr. O'Reilly
4:10PM Q&A with Queued-Up Audience Questions
Dr. O'Reilly
4:20PM H&N Cancer: Integrating Targeting the immune system with chemotherapy and targeted therapy
Dr. Langer
4:40PM Expert Panel Discussion and Final Q&A
Dr. O'Reilly
4:55PM Closing Remarks and CME/CE Post Test
Dr. Herbst
5:00PM ADJOURN

CASE-BASED LEARNING

San Francisco Airport Marriott Waterfront

Saturday, September 10, 2016

 

Overview

Back to Top

The overall objective of this new, annual, one-day live symposium plus the corresponding live Internet video simulcast for this who cannot attend the symposium in San Francisco, is to review the ongoing integration of many novel immune therapies and novel targeted therapies into the evolving standards of care, including the use of chemotherapy, for many malignancies. Standards of are care are evolving due to a continuing stream of FDA drug approvals, the evolving NCCN and ASCO guidelines and the increasing number of ongoing investigational clinical trials available to patients now.

What makes this symposium unique and highly relevant and practical to oncologists, hematologists, nurses, pharmacists, scientists and other cancer HealthCare Professionals (HCPs) is that it concurrently addresses integrating all of these new immune and targeted therapies into routine practice. This is the “real world” situation of how oncologists and hematologists and other HCPs must learn how to optimally incorporate all of these new therapies into their practices. Other oncology/hematology educational symposia either deal with immune therapy or targeted therapy, one or the other, which we believe is not the optimal way to introduce how to use these new therapies into routine practice. They must be evaluated concurrently for many reasons cited below.

For a large number of malignancies, e.g., lung cancer, pancreatic cancer, leukemia and melanoma, there are both new and emerging targeted therapies, as well as new and emerging immune therapies. For many patients these new therapies have similar, if not identical indications. Strategies employing these new immune and targeted therapies include single-agent usage, as well as combinations of immune therapy plus targeted therapy, and dual combinations of either class of therapy, and also, the optimal sequencing of these new therapies, especially with the use of established chemotherapy and chemotherapy backbones, for a large number of solid and hematologic malignancies. Treating most malignancies today involves the evaluation of numerous options of different therapies—more than ever before. This can only be adequately addressed with a symposium that reviews new immune and new targeted therapies at the same time.

Melanoma is a good example malignancy where oncologists are facing dilemmas regarding how to use targeted and immune therapies today: using monotherapy, or dual and sometimes even triple immune or targeted combination therapy. And of course, depending upon the lines of therapy, when to use and switch specific strategies in order to optimize sequencing of therapy is also a critical issue to be understood.

Several other malignancies also illustrate the educational needs for this symposium. Besides melanoma, a few questions-in-practice and dilemmas for NSCLC, pancreatic cancer and several hematologic malignancies are relevant examples and include: 1) How do clinicians select among the many new, FDA-approved checkpoint inhibitor-based strategies and their many permutations/combinations for improving outcome with NSCLC patients, plus the soon to be FDA-approved additional immune therapies? Similarly, 2) How do clinicians match NSCLC patients with specific EGFR mutations and the three generations of EGFR-directed TKI therapies, plus sequencing all of these 1st 2nd and 3rd generation EGFR-based strategies as monotherapy versus combination therapy for managing EGFR acquired resistance? 3) How do clinicians decide which is the appropriate strategy for 2nd-line non-EGFR mutated NSCLC: Is it a VEGFR-directed targeted therapy strategy or is it an immune-based (checkpoint inhibition) strategy or a taxane monotherapy? or a combination of classes? 4) How do clinicians decide which is better for improving patient outcome: either enrollment in a clinical trial to receive a new immune or targeted strategy, such as an investigational checkpoint inhibitor, or an anti-CDK/4, anti-CDK/6 or other late-stage investigational targeted therapy versus an established taxane chemotherapy approach? 5) How do hematologists begin selecting from the newest immune therapies for several lymphomas versus radiation and stem cell transplants, etc.? 6) How do oncologists integrate the most recent immune and targeted therapy data using novel JAK and BTK inhibition versus CAR T-Cell, stem cells, vaccines and other immune therapies for pancreatic cancer? These dilemmas and critical questions will be addressed at the September 10, 2016 symposium in order to optimize the potential benefits from the various and increasing new and emerging therapies that are being integrated into new standards of cancer care.

The increasing use of Next Generation Sequencing (NGS) testing for NSCLC and other malignancies has made the identification of many more biologic targets and pathways as targets that can possibly improve patient outcome. The ability of NGS to identify these new biologic targets such as BRAF, MET, MEK, ROS 1, HER2, etc., for NSCLC, breast cancer and other solid malignancies has expanded the potential list of targeted therapy options for community-based practitioners as well as has increased the options for using the new immune therapies and their combinations with both targeted therapies and in some cases, novel chemotherapies, which are under active clinical investigation. This has expanded the use of NGS testing, used as large gene panels, and also as liquid and even urine based-biopsy ctDNA testing, versus tissue-based testing and FDA-approved companion diagnostic molecular tests.

The standards of cancer care for most malignancies for the forthcoming several years will continue to be evolving with a very large number of options as existing treatment algorithms integrate new immune and new targeted therapies into the traditional systemic anticancer therapies, including chemotherapy and radiation and surgery. This symposium will emphasize and facilitate an in-depth understanding of how the new immune and novel targeted therapies are best integrated into standards of care for improving cancer patient outcome. No other educational symposium or Webinar deals with the ”real world” integration of immune and targeted therapy as does this September 10th symposium.

CME & CE CREDIT

This symposium provides 8 hours of CME credit to physicians, 8 hours of CNE credit to nurses, 8 hours of CPE credit to pharmacists, and a Certificate of Attendance for fellows and other HCPs for receiving 8 hours of credit from their professional organizations and accrediting societies.

To receive CME/CE credit, the learners attending the September 10th symposium have up to one week following the symposium to complete the required symposium survey (on line), and to successfully answer the knowledge test questions found on BioMedical Learning Institute (BMLI) Website. All of the PowerPoint® slides, recorded audio and PowerPoint presentations will be available for download and "24/7" access approximately 6 to 8 weeks following the symposium.

Bring your own “Smart Devices” to interact with the faculty

Please bring your iPhones, iPads, tablets, Androids, Laptop Computers, etc., to the September 10, 2016 symposium. If you forget, we will have extras for you to use in San Francisco. This will enable you and the other symposium participants to use your personal “smart devices” during the symposium to ask any questions of the faculty throughout the symposium from your seats in the audience, and also, to enable you and others in the audience to answer the numerous clinical care treatment questions of each faculty member during their presentations.


Educational Need

Back to Top

The educational need for this activity is the result of recent and continuing FDA approvals of new immune therapies and new targeted therapies for a large number of solid and hematologic malignancies. And because for many malignancies these new therapies have similar if not the same indications and usage, it is essential that their new applications within the current standards of care be evaluated concurrently in one symposium. With an understanding of the most current clinical trials’ data and FDA indications involving immune and targeted therapies, it will be possible for HCPs to deliver optimal patient care for many malignancies, resulting in improved outcome.


Target Audience

Back to Top

This activity is designed to meet the educational needs of medical oncologists, hematologists, radiation oncologists, surgical oncologists, pathologists, oncology pharmacists, oncology nurses/Advanced Nurse Practitioners, and other allied healthcare professionals involved in the treatment, care and management of patients with solid and hematologic malignancies that are responsive to immune and targeted therapies. Cancer Is treated optimally by a multi-disciplinary approach of clinicians, and thus, all of the aforementioned clinical specialties are targeted for invitation to this CME/CE activity.


Faculty Disclosures

Back to Top

Medical Oncology Faculty

Roy S. Herbst, MD, FRCPC (Co-Chair)
Ensign Professor of Medicine
Professor of Pharmacology
Chief of Medical Oncology
Director, Thoracic Oncology Research Program
Associate Director for Translational Research
Translational Research Program, Yale Comprehensive Cancer Center
Yale School of Medicine
New Haven, CT

Consulting Fees: AstraZeneca, Eli Lilly, Genentech/Roche, Merck, Pfizer
Contracted Research: Genentech, Merck
Scientific Advisory Board: Biothera, Diatech, Kolltan

Leo I. Gordon, MD (Co-Chair)
Abby and John Friend Professor of Cancer Research
Professor in Medicine
Director Lymphoma Program
Co-Director Hematologic Malignancies Program
Division of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Medical Director of the John and Lillian Matthews Center for Cellular Therapy
Chicago, IL

I have no real or apparent conflicts of interest to report.

Ranjana H. Advani, MD
Saul Rosenberg Professor of Lymphoma
Physician Leader of the Lymphoma Clinical Care Program
National Comprehensive Cancer Network (NCCN) non Hodgkin and Hodgkin Lymphoma (vice chair) guidelines panel
Lymphoma Core Committee of the Eastern Cooperative Oncology Group (ECOG)
Co-Chair of the National Cancer Institute Lymphoma Steering Committee
Stanford School of Medicine
Stanford, CA

Consulting Fees: BMS, Forty Seven Inc, Juno, Kyowa, Spectrum Pharmaceuticals, Sutro
Contracted Research: Genentech/Roche, Seattle Genetics, Regeneron, Infinity, Millennium, Janssen Pharmaceutica, BMS, Pharmacyclics, Kura, Merck, Agensys, Celgene
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.

Philippe Armand, MD, PhD
Assistant Professor
Department of Medicine
Harvard Medical School
Staff, Medical Oncology
Dana-Farber Cancer Institute
Boston, MA

Consulting Fees: BMS, Merck
Contracted Research: BMS, Merck, Pfizer, Affimed, Roche, Tensha
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.

Edward Garon, MD
Professor of Medicine and
Director, Department of Thoracic Oncology
UCLA Jonsson Cancer center
Los Angeles, CA

Contracted Research: AstraZeneca, Pfizer, Novartis, Genentech, Eli Lilly, BMS, Merck

Corey J. Langer, MD
Professor of Medicine
University of Pennsylvania Hospital
Director, Thoracic Oncology
Abramson Cancer Center
Perelman Center for Advanced Medicine
Philadelphia, PA

Consulting Fees: Lilly, Astra Zeneca, Merck, BMS, Genentech/Roche, AbbVie, Clovis, Ariad, Clarient, Pfizer
Contracted Research: Nektar, Merck, Clovis, Ariad, GSK, Inovio Pharmaceuticals
Other: DSMC, SWOG, AbbVie, Peregrine, Lilly, Synta
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.

Eileen M. O'Reilly, MD
Associate Director,
David M. Rubenstein Center for
Pancreatic Cancer Research
Memorial Sloan Kettering Cancer Center
New York, NY

Consulting Fees: Aduro Biotech, Agios, Array, Aslan, Astellas Pharma US, Bayer, Blueprint, Boston Scientific, BMS, Celgene, CASI, Celsion, Delcath, Eisai, EMD Serono, Gilead, Halozyme, Integragen, Ipsen, Janssen, Merck, Merrimack, Momenta, New B Innovation, NewLink Genetics, Onxeo, Opsona, Pfizer, Roche, Sanofi-Aventis, Servier, Silenseed, Sillajen, Sirtex, VAXIMM, Vicus Therapeutics, Westhaven
Contracted Research: Amgen, Astra Zeneca, BMS, Bayer, CASI, Celgene, Chugai, Exelixis, Genentech, Incyte, Lilly, Mabvax, Medimmune, Momenta, Myriad Genetics, OncoMed Pharmaceuticals Polaris Pharmaceuticals, Roche, Vicus Therapeutics
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.

John M. Pagel, MD, PhD Dsc
Clinical Hematologist
Staff Physician
Swedish Cancer Institute
Seattle, WA

I have no real or apparent conflicts of interest to report

Daniel P. Petrylak, MD
Professor of Medicine, Medical Oncology and Urology
Professor & Co-Director
Signal Transduction Research Program
Yale Comprehensive Cancer Center
Yale School of Medicine
New Haven, CT

Consulting Fees: Bayer, Bellicum, Dendreon, Sanofi Aventis, Johnson and Johnson, Exelixis, Ferring, Millennium, Medivation, Pfizer, Roche Laboratories, Tyme Pharmaceuticals
Contracted Research: Oncogenix, Progenics, Johnson and Johnson, Millennium, Celgene, Dendreon, Sanofi, Agenysis, Eli Lilly, Roche Laboratories
Ownership Interest: Bellisum, Tyme

Gregory J. Riely, MD, PhD
Medical Oncologist
Thoracic Oncology Service
Vice Chair,
Clinical Trials Office
Department of Medicine
Memorial Sloan-Kettering Cancer Center
New York, NY

Consulting Fees: Genentech

Stanley R. Riddell, MD
Professor, School of Medicine
University of Washington
Seattle Cancer Care Alliance
Seattle, WA

Scientific Advisory Board: Cell Medica, Adaptive Biotechnologies
Ownership Interest (stocks, stock options, or other ownership interest excluding diversified mutual funds): Juno Therapeutics (co-founder, equity holder)

Mario Sznol, MD
Professor of Medicine
Yale University School of Medicine
Co-Director, Yale SPORE in Skin Cancer
Yale Comprehensive Cancer Center
New Haven, CT

Consulting Fees: Genentech-Roche, Bristol-Myers, Astra-Zeneca/Medimmune, Pfizer, Novartis, Kyowa-Kirin, Immune Design, Prometheus, Nektar, Pierre-Fabre, Lilly, Merck, Alexion, Theravance, Biodesix, Vaccinex, Janssen/Johnson and Johnson, Lycera, Modulate Therapeutics, Baxalta
Scientific Advisory Board: Symphogen, Lion Biotechnologies, Amphivena – (Stock options only), Adaptive Biotechnologies– (stock options only), Intensity – (stock options only), Adaptimmune (no payments to date), Pieris (no payments to date), Omniox (no payments to date)

Margaret A. Tempero, MD
Director, UCFS Pancreas Center
Leader, Pancreas Cancer Program
Professor of Medicine
Division of Hematology and Oncology
University of California San Francisco
San Francisco, CA

Consulting Fees: Cornerstone Pharma, Eli Lilly, Novacure/MCS Biotech Resources, Opsona Therapeutics
Contracted Research: Celgene, Halozyme
Advisory Board: Gilead, Threshold Pharma/EMD Serono
Data Monitoring Committee: Fuji Film/Strategia Therapeutics
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.

Heather A. Wakelee, MD
Assistant Professor
Department of Medicine
Division of Oncology
Member, Stanford Cancer Institute
Stanford Clinical Cancer Center
Stanford, CA

Consulting Fees: Peregrine, ACEA, Pfizer, Helsinn, Genentech (uncompensated)
Contracted Research: Clovis, Exelixis, AstraZeneca, MedImmune, Genentech/Roche, BMS, Gilead, Novartis, Xcovery, Pfizer, Celgene, Pharmacyclics, Lilly
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.

Jeffrey S. Weber, MD, PhD
Director, Donald A. Adam
Comprehensive Melanoma Research Center
Senior Member, Moffitt Cancer Center
Professor and Associate Chair,
Department of Oncologic Sciences
University of South Florida
Tampa, FL

Consulting Fees: BMS, Merck, Novartis, GSK, Astra Zeneca, EMD Serono, Celldex, Nektar, Genentech, Roche
Ownership Interest (stocks, stock options, or other ownership interest excluding diversified mutual funds): Celldex, Altor, CytomX
Receipt of Intellectual Property Rights / Patent Holder: Named on a patent with Moffitt Cancer Center on predictive marker for IPI; no royalties of any kind
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.

H. Jack West, MD
Medical Director, Thoracic Oncology Program
Swedish Cancer Institute
President and CEO
Global Resource for Advancing Cancer Education
Seattle, WA

Consulting Fees: Ariad, Astra Zeneca, Boehringer-Ingelheim, BMS, Celgene, Genentech/Roche, Guardant Health, Merck, Novartis, Trovagene
Fees for non-CME/CE Services Received Directly from Commercial Interest or Their Agents (e.g. speakers’ bureaus): Ariad, Astra Zeneca, Genentech/Roche, Lilly
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.

Jeffrey Wolf, MD
Clinical Professor, Department of Medicine,
Director, Myeloma Program
Helen Diller Family Comprehensive Cancer Center
University of California San Francisco
San Francisco, CA

Consulting Fees: Takeda, Celgene, Pharmacyclics, Telomere DX
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.

Oncology Nursing Faculty

Marianne Davies, DNP, ACNP, AOCNP
Oncology Nurse Practitioner-Thoracic
Smilow Cancer Center at Yale New Haven
Yale Comprehensive Cancer Center
Assistant Professor
Yale School of Nursing
West Haven, CT

Fees for non-CME/CE Services Received Directly from Commercial Interest or Their Agents (e.g. speakers’ bureaus): Genentech, BMS, Novartis, Merck

 
 

 

Oncology Pharmacist Faculty

Jim M. Koeller, MS
Professor
University of Texas at Austin
College of Pharmacy
Pharmacotherapy Division
Adjoint Professor
University of Texas Health Science Center at San Antonio
School of Medicine
Pharmacotherapy Education & Research Center
University of Texas
Health Science Center at San Antonio
San Antonio, TX

Consulting Fees: Pfizer, Merck, Clinigen
Contracted Research: Corvida
Fees for non-CME/CE Services Received Directly from Commercial Interest or Their Agents (e.g. speakers’ bureaus): Merck, Lilly, Eisai, Pfizer

 
BioMedical Learning Institute

LEAD NURSE PLANNER
Diane D. DePew, DSN, RN-BC
I have no real or apparent conflicts of interest to report.

PLANNER & CME/CE REVIEWER
Stephen G. Madison, BSPharm, MBA, CHCP (BMLI Manager)
I have no real or apparent conflicts of interest to report.

CME/CE PEER REVIEWER
Danielle Shafer, MD
I have no real or apparent conflicts of interest to report.

Learning Objectives

Back to Top

Physicians

  1. Understand the differences in efficacy and toxicity between immunotherapies, New-Generation targeted therapies, and traditional targeted therapy and chemotherapy.
  2. Compare and contrast the various emerging and current therapies for pancreatic cancer.
  3. Compare and contrast the targeted and emerging immune therapies for leukemia.
  4. Analyze the different strategies for non-small cell lung cancer involving immune therapy versus targeted therapy and regimens with chemotherapy backbones.
  5. Devise various treatment strategies using immunotherapy and targeted therapy utilizing monotherapy, combinations and sequencing of therapies for melanoma.
  6. Assess the new and emerging data utilizing immune therapy for Hodgkin Lymphoma.
  7. Compare and contrast the use of the immune therapy for Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.
  8. Evaluate the different therapeutic strategies for Multiple Myeloma, including New-Generation targeted therapy, immunotherapy with checkpoint inhibition and with IMiDs, in both combination and monotherapy regimens.
  9. Integrate the new checkpoint inhibitor immune therapies and the established and emerging targeted strategies for metastatic renal cell carcinoma.
  10. Describe the various immune therapy strategies for metastatic Urothelial Bladder Cancer (mUBC).
  11. Compare and contrast the different immunotherapy and targeted therapy strategies for metastatic and relapsed squamous cell Head & Neck cancer.

Nurses

  1. Review the differences in efficacy and toxicity between immunotherapies, New-Generation targeted therapies, and traditional targeted therapy and chemotherapy.
  2. List the various emerging and current therapies for pancreatic cancer.
  3. Recognize the differences between the targeted and emerging immune therapies for leukemia.
  4. Recognize the different strategies for non-small cell lung cancer involving immune therapy versus targeted therapy and regimens with chemotherapy backbones.
  5. Identify various treatment strategies using immunotherapy and targeted therapy utilizing monotherapy, combinations and sequencing of therapies for melanoma.
  6. Recall the new and emerging data utilizing immune therapy for Hodgkin Lymphoma.
  7. Outline the use of the immune therapy for Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.
  8. Define the different therapeutic strategies for Multiple Myeloma, including New-Generation targeted therapy, immunotherapy with checkpoint inhibition and with IMiDs, in both combination and monotherapy regimens.
  9. Integrate the new checkpoint inhibitor immune therapies and the established and emerging targeted and immune strategies for renal cell carcinoma.
  10. Describe the various immune therapy strategies for metastatic Urothelial Bladder Cancer (mUBC).
  11. List the different immunotherapy and targeted therapy strategies for metastatic and relapsed squamous cell Head & Neck cancer.

Pharmacists

  1. Review the differences in efficacy and toxicity between immunotherapies, New-Generation targeted therapies, and traditional targeted therapy and chemotherapy.
  2. List the various emerging and current therapies for pancreatic cancer.
  3. Recognize the differences between the targeted and emerging immune therapies for leukemia.
  4. Recognize the different strategies for non-small cell lung cancer involving immune therapy versus targeted therapy and regimens with chemotherapy backbones.
  5. Identify various treatment strategies using immunotherapy and targeted therapy utilizing monotherapy, combinations and sequencing of therapies for melanoma.
  6. Recall the new and emerging data utilizing immune therapy for Hodgkin Lymphoma.
  7. Outline the use of the immune therapy for Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.
  8. Define the different therapeutic strategies for Multiple Myeloma, including New-Generation targeted therapy, immunotherapy with checkpoint inhibition and with IMiDs, in both combination and monotherapy regimens.
  9. Integrate the new checkpoint inhibitor immune therapies and the established and emerging targeted and immune strategies for renal cell carcinoma.
  10. Describe the various immune therapy strategies for metastatic Urothelial Bladder Cancer (mUBC).
  11. List the different immunotherapy and targeted therapy strategies for metastatic and relapsed squamous cell Head & Neck cancer.

CME/CE Accreditation and Credit Designation

Back to Top

Physicians

The BioMedical Learning Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The BioMedical Learning Institute designates this live activity for a maximum of 8.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacists

The BioMedical Learning Institute is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

UAN: 0838-0000-16-003-L01-P
Credits: 8.25 hours (0.825 ceu)
Type of Activity: Knowledge

To receive CE contact hour credit, attendance at the entire activity and the successful completion of the post‐test and evaluation form is required.

Nurses

The BioMedical Learning Institute is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

The BioMedical Learning Institute designates this educational activity for 8.25 contact hours.

Accreditation by the American Nurses Credentialing Center's Commission on Accreditation refers to recognition of educational activities and does not imply approval or endorsement of any product.

To receive CE contact hour credit, attendance at the entire activity and the successful completion of the post‐test and evaluation form is required.

Other

Physician Assistants: AAPA accepts certificates of attendance for educational activities certified for Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician Assistants may receive a maximum of 8.25 hours of Category 1 credit for attending this symposium.

Fellows will receive a certificate of attendance that they can submit to their accrediting organizations for continuing education credit.


Location of this Symposium

Back to Top

San Francisco Airport Marriott Waterfront
1800 Old Bayshore Highway
Burlingame, California 94010

The discounted room rates of $172 will expire on August 12, 2016. Please note that there are two ways to reserve a room for this symposium. You may click here to book online or call 650-692-9100 and mention that the reservation is for the BMLI symposium in order to receive the reduced rate.


Live Internet Video Simulcast

Back to Top

Participants of the live simulcast will earn either CME or CE credit in the same manner as participants attending the live meeting. For registered participants: Instructions will be emailed approximately 1 week prior to the event. Kindly check your SPAM folder if you have not received the instructions.


Exhibit Information

Back to Top

There is an opportunity to exhibit at this symposium. Please send an email to exhibits@bmli.com for more information or call 214-269-2014 (All calls will be answered within 24 hours).

EXHIBIT FEES:

  • If your company is a "commercial supporter" for CME/CE of this symposium; $799 for one table; $999 for 2 tables.
  • If your company is not a "commercial supporter" for CME/CE of this symposium $1,499 for one table; $2,499 for 2 tables.
  • If your company is an Advocacy Group, such as Bonnie J. Addario Lung Cancer Foundation, LUNGevity, Free to Breathe, Lung Cancer Alliance, American Lung Association, etc., there is NO fee for Exhibit space.

TERMS FOR EXHIBITORS:

  • Exhibitors who are not registered attendees to the symposium will not have access to the buffet breakfast or the buffet Lunch with the Professors.
  • The Exhibitors will not have access to the scientific sessions unless they are registered for the activity.

Educational Support

Sincere appreciation is extended to companies providing support for this independent educational activity.

Genentech
Merck
Novartis
Lilly
Celgene
Boehringer Ingelheim
Ariad
Foundation Medicine
Aduro Biotech
Table of Contents
Educational Partner